Investigating a Personalized Approach to Anti-Platelet Therapy
ConditionHigh Risk Bleeding
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation
About this trial
RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.
Eligibility criteria
Qualifiers
Age >18 years old
Receiving PCI with stenting
Disqualifiers
Inability to take ticagrelor
Inability to take clopidogrel
Not expected to survive >48hours
Not able to complete a buccal swab
Trial design
Treatments tested in this trial
- Genotyping guided therapy for anti-platelet management
Treatment groups
1,760 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov